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Summary	
Limited	data	exist	on	platelet	transfusion	during	postpartum	haemorrhage.	We	
retrospectively	analysed	a	single-centred	consecutive	cohort	(n=347)	with	moderate-to-
severe	postpartum	haemorrhage	transfused	according	to	national	guidelines.	12/347	(3.4%)	
women	required	platelets.	There	were	no	differences	between	women	who	did	and	did	not	
receive	platelets	with	respect	to	age,	initiation	of	labour	or	mode	of	delivery.	Women	
receiving	platelets	had	a	lower	platelet	count	than	women	who	did	not	receive	platelets	
pre-haemorrhage	(median	135	vs	224	X10
9
.l
-1
)	and	at	diagnosis	of	postpartum	haemorrhage	
(median	114	vs	193	X10
9
.l
-1
)	with	6	out	of	12	women	who	received	platelets	being	
thrombocytopenic	pre-delivery.	Placental	abruption	was	associated	with	the	highest	rate	of	
platelet	transfusion	3/14(21%).	If	antenatal	thrombocytopenia	or	consumptive	
coagulopathy	were	not	present,	platelets	were	only	required	for	bleeds	exceeding	5000	ml.	
Early	formulaic	platelet	transfusion	would	have	resulted	in	many	women	receiving	platelets	
unnecessarily.	Using	current	guidelines	the	need	for	platelet	transfusion	is	uncommon	
without	antenatal	thrombocytopenia,	consumptive	coagulopathy	or	bleeds	>5000	ml.	We	
found	no	evidence	to	support	early	fixed-ratio	platelet	transfusion.		
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Introduction	
Postpartum	haemorrhage	is	the	leading	cause	of	maternal	mortality	globally	[1,	2].	In	
the	UK,	postpartum	haemorrhage	causes	75%	of	severe	obstetric	morbidity	[3]	and	is	an	
important	cause	of	direct	maternal	mortality	[4].	Postpartum	haemorrhage	may	be	
associated	with	the	depletion	of	coagulation	factors	and	platelets	due	to	dilutional	and	
consumptive	coagulopathies	[5-7].	Studies	have	described	the	consequences	of	reduced	
coagulation	factors	and	their	replacement	with	fresh	frozen	plasma	(FFP),	cryoprecipitate	
and	fibrinogen	concentrate	[8-12]	but	there	are	limited	data	on	the	need	for	platelet	
transfusion.		
The	optimal	platelet	transfusion	trigger	and	target	count	is	unknown,	however,	
guidelines	suggest	that	platelets	should	be	transfused	at	75	x10
9
.l
-1
	to	maintain	a	count	
above	50	x10
9
.l
-1
	[13-16].	There	is	a	trend	to	adopt	fixed-ratio	platelet	transfusion	in	
postpartum	haemorrhage	[12,	17-20],	a	practice	directly	extrapolated	from	major	trauma	
[21]	despite	the	coagulopathies	of	trauma	and	obstetric	bleeding	being	markedly	different	
[5-7,	22-24].	No	studies	have	investigated	whether	this	is	an	appropriate	or	safe	strategy,	
and	some	groups	describe	good	outcomes	with	low	rates	of	platelet	transfusion	[25-27].	
Changes	in	platelet	count	during	postpartum	haemorrhage	are	not	well	described.	In	
this	study	we	have	analysed	our	previously-published	dataset	that	was	used	to	investigate	
the	effect	of	fibrinogen	and	Fibtem	levels	on	the	progression	of	postpartum	haemorrhage	
[28].	These	data	provides	an	opportunity	to	document	changes	in	the	platelet	count	and	the	
requirement	for	platelet	transfusion	in	a	consecutive	cohort	of	women	during	moderate	or	
severe	postpartum	haemorrhage.		
	
Methods	
The	study	was	approved	by	the	South	East	Wales	Research	Ethics	Committee.	Data	
were	collected	prospectively	on	women	experiencing	moderate	or	severe	postpartum	
haemorrhage	between	April	2012	-	March	2013	in	a	single	hospital	[28].	Women	were	
included	if,	in	the	opinion	of	the	recruiting	clinician,	they	had	bled	more	than	approximately	
1500	ml,	or	if	they	bled	approximately	1000-1500	ml	and	had	an	additional	risk	factor	
(caesarean	section,	uterine	atony,	placental	abruption,	placenta	praevia,	microvascular	
oozing	or	cardiovascular	instability).		
At	study	entry	a	full	blood	count	(FBC)	was	taken.	Subsequent	FBCs	and	decisions	to	
transfuse	platelets	were	taken	at	the	discretion	of	the	treating	clinicians	and	were	based	on	
national	and	local	guidelines	[14,	15].	The	last	platelet	count	before	the	haemorrhage	was	
identified,	taken	on	admission	to	the	delivery	suite	or	in	the	late	antenatal	period.	
Additional	variables	included	patient	characteristics,	precipitants	of	haemorrhage,	
gravimetrically-measured	total	blood	loss	[29],	transfusion	of	red	blood	cells	(RBC),	FFP	and	
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platelets.	The	main	precipitant	of	the	postpartum	haemorrhage	was	recorded	as	
surgical/genital	tract	trauma	including	uterine	rupture,	placental	abruption,	adherent	or	
retained	placenta,	placenta	praevia	or	uterine	atony.	If	no	precipitant	was	recorded,	the	
case	was	retrospectively	allocated	to	one	of	the	above	groups.		
The	largest	fall	in	platelet	count	was	calculated	by	subtracting	the	lowest	platelet	
count	measured	during	the	bleed	from	either	the	last	platelet	count	before	haemorrhage	or	
that	at	study	entry,	whichever	was	higher	(if	the	platelet	count	increased	the	‘fall’	was	
defined	as	zero).	Data	were	analysed	using	SPSS	version	20	(IBM,	Amrock,	NY,	USA).	
Receiver	operator	characteristic	(ROC)	curves	were	used	to	investigate	whether	
platelet	count	before	the	bleed	had	started	or	at	study	entry	were	predictive	of	progression	
to	bleeds	>	2500	ml	or	the	need	for	platelet	transfusion.			
	
Results	
There	were	6187	deliveries	during	the	study	period.	Three	hundred	and	fifty-six	(six	
percent)	women	had	a	moderate	or	severe	postpartum	haemorrhage.	Full	data	were	
available	for	347	women	and	are	reported	here.	Characteristics	of	the	women	are	shown	in	
Table	1.	In	29	cases	the	retrospective	assessment	of	blood	loss	was	less	than	the	
recruitment	criteria.		
Twelve	women	received	platelets,	comprising	3.4%	of	those	who	had	a	postpartum	
haemorrhage.	Women	who	received	a	platelet	transfusion	were	of	similar	age,	body	mass	
index,	 and	 labour	 and	 delivery	 characteristics	 to	 women	 who	 did	 not.	 The	 women	 who	
received	platelets	had	similar	blood	loss	at	study	entry	to	those	that	did	not,	but	had	larger	
total	blood	 losses;	a	higher	proportion	of	women	who	received	platelets	had	blood	 loss	>	
2500	ml	compared	with	those	who	did	not.	Women	who	received	platelets	were	more	likely	
to	have	had	a	placental	abruption	(Table	1).	The	haemoglobin	concentration	measured	on	
the	 last	FBC	before	haemorrhage	and	the	FBC	at	study	entry	was	similar	between	women	
who	did	 and	did	 not	 receive	 platelets.	Women	who	 received	platelets	 had	 lower	 platelet	
counts	 both	 before	 haemorrhage	 and	 at	 study	 entry,	 and	 lower	 Clauss	 fibrinogen	 and	
Fibtem	A5	at	study	entry,	suggestive	of	consumptive	coagulopathy	(Table	1).		
Neither	platelet	count	before	haemorrhage	nor	at	study	entry	were	predictive	of	
haemorrhage	>	2500	ml	(ROC	area	under	the	curve	(95%	CI)	0.50	(0.40-0.60)	and	0.45	(0.35-
0.55)	respectively)	or	the	need	for	RBC	transfusion	(ROC	0.50	(0.43-0.57)	and	0.47	(0.41-
0.54	respectively).	The	platelet	count	before	haemorrhage	and	at	study	entry	were	
predictive	of	the	need	for	a	platelet	transfusion	(ROC	0.85	(0.73-0.97)	and	0.84	(0.96-0.72)	
respectively).	
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The	platelet	count	before	haemorrhage,	at	study	entry	and	the	lowest	platelet	count	
recorded	according	to	the	cause	of	haemorrhage	are	shown	in	Table	2.	In	14	cases	the	cause	
of	bleeding	was	not	recorded	in	the	study	data,	but	was	retrospectively	identified	based	on	
the	clinical	records.	Platelet	counts	before	haemorrhage	and	at	study	entry	were	similar	for	
all	causes	of	haemorrhage.	The	median	(IQR	[range])	largest	fall	in	platelet	count	for	the	
whole	cohort	was	48	(25-71	[0-257])	x10
9
.l
-1
.	After	study	entry	there	was	a	small	fall	in	
platelet	count	5	(0-32	[0-168])	x10
9
.l
-1
.		
The	two	most	common	causes	of	postpartum	haemorrhage,	surgical/trauma-
induced	and	uterine	atony,	were	associated	with	median	falls	after	study	entry	of	1	x10
9
.l
-1
	
and	7	x10
9
.l
-1
	respectively.	A	platelet	count	<	75	x10
9
.l
-1
	was	seen	in	eight	(2%)	women	with	
postpartum	haemorrhage.	The	proportion	of	women	with	a	lowest	platelet	count	<	75	
x10
9
.l
-1	
was	highest	for	placental	abruption	(1/14,	7%)	and	for	uterine	atony	it	was	(2/148,	
1%).	
If	the	platelet	count	is	adjusted	to	take	account	of	platelet	transfusion	by	subtracting	
30	x10
9
.l
-1	
per	unit	of	platelets	transfused	from	the	measured	count	[30],	11	(3%)	women	
would	have	had	a	platelet	count	<	75	x10
9
.l
-1
.	
Women	who	received	platelets	fell	into	three	categories:	thrombocytopenia	before	the	
bleed;	placental	abruption		and	massive	haemorrhage	>	5000	ml	(Table	3).	The	causes	of	
thrombocytopenia	before	the	bleed	were	pre-clampsia,	gestational,	hereditary	and	immune	
mediated.	One	woman	was	diagnosed	with	gestational	thrombocytopenia	at	the	time	of	the	
bleed	but	subsequently	continued	to	have	a	platelet	count	of	about	100	x	10
9
/L	post	
delivery	and	may	have	had	a	mild	immune	thrombocytopenia.		Women	with	postpartum	
haemorrhage	due	to	abruption	were	the	most	likely	to	receive	platelets	(3/14,	21%).	
Platelets	were	given	to	5/141	(4%)	women	with	trauma-induced	bleeding,	although	all	5	
were	thrombocytopenic	before	the	bleed	onset.	Of	the	6	women	with	normal	platelet	
counts	prior	to	the	onset	of	bleeding,	2	had	abruptions	and	one	an	amniotic	fluid	embolism.	
The	remaining	3	women	had	very	large	bleeds	between	5000-5500	ml	and	all	received	≥	8	
units	RBCs	and	≥	12	units	FFP.	In	the	study	5	women	had	a	postpartum	haemorrhage	≥5000	
mL,	4	were	transfused	platelets	and	in	the	single	case	that	was	not	transfused	the	lowest	
measured	count	was	79	x10
9
.l
-1
.		
	
If	a	strategy	of	fixed-ratio	platelet	transfusion	without	monitoring	had	been	used,	
then	4:	4:	1	(RBC:	FFP:	platelet	pool)	replacement	would	have	resulted	in	32	women	
receiving	platelets.	Of	these	32	women,	seven	were	transfused	platelets	and	25	were	not;	
conversely	five	women	who	received	platelets	would	not	have	been	transfused.	A	strategy	
of	6:	4:	1	replacement	would	have	resulted	in	nine	women	receiving	platelets.	Of	these	nine	
women,	four	were	transfused	platelets	and	five	were	not,	whilst	eight	women	who	received	
platelets	would	not	have	been	transfused.	
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Discussion	
This	study	shows	that	platelet	transfusion	is	rarely	required	to	treat	moderate	or	
severe	postpartum	haemorrhage	if	current	guidelines	are	followed	[13,	14,	16,	31].	The	
incidence	of	platelet	transfusion	was	3.4%	of	cases	of	moderate	or	severe	postpartum	
haemorrhage.	Platelets	were	most	commonly	given	to	women	who	were	thrombocytopenic	
before	the	onset	of	haemorrhage,	or	for	consumptive	coagulopathies	caused	by	placental	
abruption	and	amniotic	fluid	embolism.	Platelet	transfusion	was	also	required	for	massive	
haemorrhage	≥	5000	ml	in	the	absence	of	antenatal	thrombocytopenia	or	a	consumptive	
coagulopathy.	There	was	no	difference	between	the	women	who	did	or	did	not	receive	
platelets	with	respect	to	age,	body	mass	index,	induction	of	labour	or	mode	of	delivery.	The	
only	precipitant	of	haemorrhage	associated	with	an	increased	need	for	platelet	transfusion	
was	placental	abruption.	
This	cohort	is	typical	of	UK	tertiary	practice,	with	a	5.8%	incidence	of	moderate	or	
severe	postpartum	haemorrhage	and	0.6%	incidence	of	haemorrhage	>	2500	ml	[3].	Our	
management	at	the	time	of	the	study	was	based	on	national	and	local	guidelines	[14,	15],	
which	recommended	transfusing	platelets	if	the	count	was	<	75	x10
9
.l
-1
	to	prevent	a	fall	to	<	
50	x10
9
.l
-1
.	These	guidelines	appear	to	have	been	followed	because	only	two	women	who	
had	a	platelet	count	<	75	x10
9
.l
-1
	(counts	of	72	x10
9
.l
-1
	and	74	x10
9
.l
-1
,	measured	after	the	
postpartum	haemorrhage	had	resolved)	did	not	receive	platelets	and	both	women	with	a	
platelet	count	<	50	x10
9
.l
-1
	received	platelets.	Retrospective	review	may	suggest	a	tendency	
to	over-transfuse	platelets	because,	in	some	cases,	platelets	were	transfused	to	maintain	a	
count	>	75	x10
9
.l
-1
	rather	than	>	50	x10
9
.l
-1
.	Platelets	were	given	to	some	women	after	the	
postpartum	haemorrhage	had	resolved	to	reduce	the	risk	of	recurrence.	We	were	not	able	
to	assess	whether	there	was	variability	in	practice	between	clinicians.	There	does	not	
appear	to	have	been	a	tendency	to	under-transfuse	platelets	in	this	cohort,	supporting	the	
conclusion	that	the	need	for	platelet	transfusion	is	uncommon	in	postpartum	haemorrhage.		
Women	who	were	transfused	platelets	had	lower	platelet	counts	before	
haemorrhage	and	at	study	entry	than	those	who	were	not	transfused	platelets.	In	contrast,	
haemoglobin	concentration	was	similar	for	women	who	were	or	were	not	transfused	
platelets,	suggesting	that	thrombocytopenia	at	these	measurement	points	was	not	a	
consequence	of	the	amount	of	haemorrhage.	Half	of	the	women	who	were	given	a	platelet	
transfusion	had	thrombocytopenia	before	haemorrhage.	This	was	either	inherited,	
gestational/immune	mediated,	or	due	to	abruption	or	pre-eclampsia.	In	one	case	the	
aetiology	was	unclear	and	may	have	been	due	to	gestational	or	immune	thrombocytopenia.	
All	bleeds	in	these	cases	were	precipitated	by	surgical	intervention.	Some	platelet	
transfusions	could,	therefore,	be	anticipated	before	delivery.	
Placental	abruption	was	the	cause	of	bleeding	associated	with	the	highest	
proportion	of	women	requiring	platelet	transfusion,	secondary	to	consumptive	
coagulopathy	[6,	7,	23,	32].	The	importance	of	consumption	in	placental	abruption	was	
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confirmed	because	all	cases	that	required	platelets	also	had	severe	hypofibrinogenamia	<	
2g.l
-1
	at	study	entry.	Furthermore,	women	who	received	platelets	for	any	reason	had	lower	
fibrinogen	and	Fibtem	A5	at	study	entry	than	those	who	did	not.		
Amniotic	fluid	embolism	also	causes	consumption	[23].	The	single	case	reported	
here	had	a	fibrinogen	<	0.5	g.l
-1
	at	diagnosis	and	a	lowest	platelet	count	of	85	x10
9
.l
-1
	despite	
4	platelet	pools	suggesting	that	the	nadir	would	have	been	well	below	75	x10
9
.l
-1
	if	platelets	
had	not	be	given.	Thrombocytopenia	due	to	consumption	is,	therefore,	an	important	cause	
of	low	platelets	during	postpartum	haemorrhage.	A	low	Fibtem	A5	early	in	the	bleed	may	be	
a	useful	indicator	that	consumption	is	likely	and	the	likelihood	of	requiring	platelet	
transfusion	is	increased	[32].		
Women	who	received	platelets	had	larger	total	blood	loss	than	those	that	did	not,	
however,	haemorrhage	<	5000	ml	secondary	to	atony	or	surgery/trauma	was	not	associated	
with	platelet	counts	<	75	x10
9
.l
-1
.	Postpartum	haemorrhage,	in	the	absence	of	consumption	
or	antenatal	thrombocytopenia,	is	therefore	an	uncommon	indication	for	platelets	unless	
very	large	haemorrhage	occur	suggesting	that	early	unmonitored	platelet	transfusion	during	
postpartum	haemorrhage	would	result	in	many	unnecessary	transfusions.	All	women	who	
received	platelets	secondary	to	massive	haemorrhage	in	our	study	required	≥	8	units	RBCs.	
In	a	recent	study	of	women	receiving	≥	8	units	RBCs	with	median	blood	loss	6000	ml,	
platelets	<	75	x10
9
.l
-1
	were	seen	in	over	50%	of	cases	confirming	that	very	large	
haemorrhages	are	an	important	reason	for	platelet	transfusion	[33].	Recent	guidelines	
suggest	transfusing	platelets	if	8	units	of	RBC	have	been	transfused	and	a	platelet	count	is	
not	available	[16].		
A	case	control	study	reported	that	a	platelet	count	<	80	x10
9
.l
-1
	at	the	time	of	
delivery	was	associated	with	an	increased	risk	of	postpartum	haemorrhage	[34].	A	further	
study	has	reported	that	platelets	<	100	x10
9
.l
-1
	and	fibrinogen	<	3g.l
-1
	was	associated	with	a	
19-fold	increased	risk	of	postpartum	haemorrhage	[35].	Our	data	showed	that	the	platelet	
count	prior	to	bleeding	and	at	study	entry	were	not	associated	with	progression	to	
haemorrhage	≥	2500	ml	or	the	need	for	RBC	transfusion,	although	most	women	in	the	study	
had	moderate	or	severe	postpartum	haemorrhage	at	inclusion.	Low	fibrinogen	has	
previously	been	shown	to	be	associated	with	progression	to	severe	postpartum	
haemorrhage	in	our	cohort	[28]	and	this	may	suggest	that	hypofibrinogenaemia	is	a	more	
significant	risk	factor	for	progression	to	severe	postpartum	haemorrhage	than	
thrombocytopenia.		
The	average	fall	in	platelets	during	postpartum	haemorrhage	was	small,	particularly	
for	atony	and	trauma-related	bleeds.	A	previous	report	measured	serial	platelet	counts	
during	severe	postpartum	haemorrhage	and	also	found	minimal	changes	in	platelet	count	
[36].	This	suggests	that,	in	the	absence	of	consumption,	platelet	counts	remain	relatively	
stable	until	very	large	bleeds	have	occurred.	
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Some	authors	suggest	that	fixed-ratio	platelet	transfusion	is	an	appropriate	strategy	
during	severe	postpartum	haemorrhage	[17,	18,	20].	In	our	cohort	we	estimate	that,	if	fixed-
ratio	transfusion	had	been	used,	multiple	platelets	would	have	been	given	to	women	with	
platelets	counts	well	above	those	recommended	in	guidelines	and	women	with	clinically	
significant	thrombocytopenia	would	not	have	received	platelets.	This	finding	is	supported	by	
others	who	have	moved	away	from	formulaic	shock	packs	and	shown	a	substantial	decrease	
in	platelet	transfusion	associated	with	improved	outcomes	[26,	27].	
Weaknesses	of	the	study	are	that	it	is	a	retrospective	analysis	of	a	cohort	recruited	
to	analyse	the	impact	of	fibrinogen	on	subsequent	progression	of	postpartum	haemorrhage.	
Although	the	platelet	count	at	study	entry	was	taken	at	a	standardised	time,	all	other	counts	
were	at	the	clinicians’	discretion	and	so	varied	widely.	Platelet	counts	were	not	always	
performed	immediately	prior	to	transfusion	and	so	the	lowest	platelet	count	may	not	have	
been	recorded.	It	is	not	known	whether	the	platelet	transfusions	given	during	this	study	
affected	clinical	outcomes.		
This	study	shows	that	platelet	transfusion	is	rarely	required	in	postpartum	
haemorrhage	and	identifies	pre-delivery	thrombocytopenia,	consumptive	coagulopathies	
and	massive	postpartum	haemorrhage	(>	5000	ml)	as	risk	factors.	We	found	no	evidence	to	
support	fixed-ratio	platelet	transfusion	for	postpartum	haemorrhage.	Recent	guidelines	[13]	
also	recommended	against	fixed-ratio	platelet	transfusion	during	postpartum	haemorrhage	
but	suggest	that	if	8	units	of	RBCs	have	been	transfused	and	no	platelet	count	is	available	
then	a	pool	of	platelets	may	be	given	[16].	
Key	tools	for	the	physician	to	identify	patients	most	at	risk	of	requiring	platelet	
transfusion	in	postpartum	haemorrhage	are	knowledge	of	the	pre-delivery	platelet	count	to	
identify	pre-existing	thrombocytopenia,	early	identification	of	consumptive	coagulopathies	
during	bleeds	(potentially	through	point	of	care	testing),	and	meticulous	contemporaneous	
measurement	of	blood	loss.	In	the	absence	of	pre-existing	thrombocytopenia,	a	
consumptive	bleed	or	blood	loss	greater	than	5000	ml	it	appears	that	the	risk	of	a	critically	
low	platelet	count	requiring	platelet	transfusion	in	postpartum	haemorrhage	is	very	low	and	
that	including	platelets	in	massive	haemorrhage	packs	for	postpartum	haemorrhage	is	
unnecessary	until	8	units	of	RBC	have	been	reached.	
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